Formoterol dry-powder inhalation - AstraZeneca

Drug Profile

Formoterol dry-powder inhalation - AstraZeneca

Alternative Names: Eformoterol dry-powder inhalation - AstraZeneca; Formoterol fumarate dry-powder inhalation - AstraZeneca; Formoterol Turbuhaler; Oxez Turbuhaler; Oxeze Turbuhaler; Oxis; Oxis Turbuhaler

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease; Exercise-induced asthma

Most Recent Events

  • 01 Dec 2016 AstraZeneca completes a phase II trial for Chronic obstructive pulmonary disease in USA (Inhalation) (NCT02796651)
  • 01 Jun 2016 Phase-III clinical trials in Chronic obstructive pulmonary disease in USA (Inhalation)
  • 01 Jun 2016 AstraZeneca initiates a phase II trial for Chronic obstructive pulmonary disease in USA (Inhalation) (NCT02796651)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top